The current global COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

Vaccination and administration of monoclonal antibody cocktails are effective tools to control
the progression of infectious diseases and to terminate pandemics such as COVID-19 …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has accumulated more than
700 million infection cases and 6.9 million deaths. New variants have affected antibody …

Infection with SARS‐CoV‐2 elicits robust antibody responses in some patients, with a
majority of the response directed at the receptor binding domain (RBD) of the spike surface …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 770 million cases and> …